Should women with HPV-related noncervical cancers be considered at high risk for cervical cancer?

REFERENCES

1. ↵
   1. Moscicki AB,
   2. Darragh TM,
   3. Berry-Lawhorn JM, et al

   . Screening for anal cancer in women. J Low Genit Tract Dis 2015; 19(3 suppl 1):S27–S42. doi:10.1097/LGT.0000000000000117

   OpenUrlCrossRefPubMed
2. 1. Myers ER,
   2. McCrory DC,
   3. Nanda K,
   4. Bastian L,
   5. Matchar DB

   . Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000;151(12):1158–1171. doi:10.1093/oxfordjournals.aje.a010166

   OpenUrlCrossRefPubMed
3. ↵
   1. Beachler DC,
   2. Kreimer AR,
   3. Schiffman M, et al

   . Multisite HPV16/18 vaccine efficacy against cervical, anal, and oral HPV infection. J Natl Cancer Inst 2015; 108(1):djv302. doi:10.1093/jnci/djv302

   OpenUrlCrossRefPubMed
4. ↵
   1. Gillison ML,
   2. Chaturvedi AK,
   3. Anderson WF,
   4. Fakhry C

   . Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol 2015;33(29):3235–3242. doi:10.1200/JCO.2015.61.6995

   OpenUrlAbstract/FREE Full Text
5. ↵
   1. National Cancer Institute

   . SEER cancer statistics review (CSR) 1975–2015. https://seer.cancer.gov/archive/csr/1975_2015/. Accessed August 5, 2020.
6. ↵
   1. Watson M,
   2. Soman A,
   3. Flagg EW, et al

   . Surveillance of high-grade cervical cancer precursors (CIN III/AIS) in four population-based cancer registries, United States, 2009–2012. Prev Med 2017; 103:60–65. doi:10.1016/j.ypmed.2017.07.027

   OpenUrlCrossRef
7. ↵
   1. Hariri S,
   2. Bennett NM,
   3. Niccolai LM, et al

   . Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States—2008–2012. Vaccine 2015;33(13):1608–1613. doi:10.1016/j.vaccine.2015.01.084

   OpenUrlCrossRefPubMed
8. ↵
   1. Van Dyne EA,
   2. Henley SJ,
   3. Saraiya M,
   4. Thomas CC,
   5. Markowitz LE,
   6. Benard VB

   . Trends in human papillomavirus-associated cancers— United States, 1999–2015. MMWR Morb Mortal Wkly Rep 2018; 67(33):918–924. doi:10.15585/mmwr.mm6733a2

   OpenUrlCrossRef
9. ↵
   1. National Cancer Institute

   . Cancer stat facts: anal cancer. https://seer.cancer.gov/statfacts/html/anus.html. Accessed August 5, 2020.
10. ↵
    1. Saleem AM,
    2. Paulus JK,
    3. Shapter AP,
    4. Baxter NN,
    5. Roberts PL,
    6. Ricciardi R

    . Risk of anal cancer in a cohort with human papillomavirus-related gynecologic neoplasm. Obstet Gynecol 2011;117(3):643–649. doi:10.1097/AOG.0b013e31820bfb16

    OpenUrlCrossRefPubMed
11. ↵
    1. Hoots BE,
    2. Palefsky JM,
    3. Pimenta JM,
    4. Smith JS

    . Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 2009;124(10):2375–2383. doi:10.1002/ijc.24215

    OpenUrlCrossRefPubMed
12. 1. Alemany L,
    2. Saunier M,
    3. Alvarado-Cabrero I, et al

    . Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer 2015;136(1):98–107. doi:10.1002/ijc.28963

    OpenUrlCrossRef
13. ↵
    1. Morel A,
    2. Neuzillet C,
    3. Wack M, et al

    . Mechanistic signatures of human papillomavirus insertions in anal squamous cell carcinomas. Cancers (Basel) 2019;11(12):1846. doi:10.3390/cancers11121846

    OpenUrlCrossRef
14. ↵
    1. Perkins RB,
    2. Guido RS,
    3. Castle PE, et al

    . 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 2020; 24(2):102–131. doi:10.1097/LGT.0000000000000525

    OpenUrlCrossRef
15. ↵
    1. Moscicki AB,
    2. Flowers L,
    3. Huchko MJ, et al

    . Guidelines for cervical cancer screening in immunosuppressed women without HIV infection. J Low Genit Tract Dis 2019;23(2):87–101. doi:10.1097/LGT.0000000000000468

    OpenUrlCrossRef
16. ↵
    1. National Cancer Institute

    . Diethylstilbestrol (DES) and cancer. https://www.cancer.gov/about-cancer/causes-prevention/risk/hormones/desfact-sheet. Accessed August 5, 2020.
17. ↵
    1. Fokom Domgue J,
    2. Messick C,
    3. Milbourne A, et al

    . Prevalence of high-grade anal dysplasia among women with high-grade lower genital tract dysplasia or cancer: results of a pilot study. Gynecol Oncol 2019;153(2):266–270. doi:10.1016/j.ygyno.2019.02.024

    OpenUrlCrossRef
18. ↵
    1. Eleutério J Jr.,
    2. Cavalcante LR,
    3. Gonçalves AKS,
    4. Eleutério RMN,
    5. Giraldo PC

    . Prevalence of high-risk HPV and atypia in liquid-based cytology of cervical and intra-anal specimens from kidney-transplanted women. Diagn Cytopathol 2019; 47(8):783–787. doi:10.1002/dc.24180

    OpenUrlCrossRef
19. ↵
    1. Chin-Hong PV,
    2. Palefsky JM

    . Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis 2002; 35(9):1127–1134. doi:10.1086/344057

    OpenUrlCrossRefPubMed
20. ↵
    1. Parkin DM,
    2. Bray F

    . Chapter 2: the burden of HPV-related cancers. Vaccine 2006; 24(suppl 3):S3/11–S3/25. doi:10.1016/j.vaccine.2006.05.111

    OpenUrlCrossRef
21. ↵
    1. Hillman RJ,
    2. Berry-Lawhorn JM,
    3. Ong JJ, et al

    . International Anal Neoplasia Society guidelines for the practice of digital anal rectal examination. J Low Genit Tract Dis 2019;23(2):138–146. doi:10.1097/LGT.0000000000000458

    OpenUrlCrossRef
22. ↵
    1. National AIDS Treatment Advocacy Program

    . NYS guidelines recommendations on anal Pap smears. http://www.natap.org/2010/HIV/032510_01.htm. Accessed August 5, 2020.
23. ↵
    1. Lili E,
    2. Chatzistamatiou K,
    3. Kalpaktsidou-Vakiani A,
    4. Moysiadis T,
    5. Agorastos T

    . Low recurrence rate of high-grade cervical intraepithelial neoplasia after successful excision and routine colposcopy during follow-up. Medicine (Baltimore) 2018; 97(4):e9719. doi:10.1097/MD.0000000000009719

    OpenUrlCrossRef